<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7222554\results\search\testTrace\results.xml">
  <result pre="pandemic and where we currently stand. Graphical abstract Keywords:â€‚ COVID-19" exact="infection" post="repurposed therapies SARS-CoV-2 vaccine viruses page-count: Background Viruses are"/>
  <result pre="On 7 January 2020, the authorities in China declared the" exact="isolation" post="of the new CoV type [12]. On 12th January,"/>
  <result pre="in Wuhan [3,14]. Once the first case was identified, the" exact="infection" post="was possibly spread from animal to human as a"/>
  <result pre="of the disease once it has been acquired [26,28]. SARS-CoV-2" exact="infection" post="is primarily thought to transmit from human-to-human among individuals"/>
  <result pre="quickly and sustainably among individuals [29]. Symptoms of catching an" exact="infection" post="Information from public care bodies, reviews and guidelines provide"/>
  <result pre="with clinical and ventilatory requirements that are needed for this" exact="diagnosis" post="[13]. This condition indicates a severe new respiratory problem"/>
  <result pre="shock presented as hyperbilirubinemia laboratory results [31]. Clinical progression &amp;amp;" exact="diagnosis" post="The quest through Google dataset for SARS-CoV-2 diagnosis (as"/>
  <result pre="progression &amp;amp; diagnosis The quest through Google dataset for SARS-CoV-2" exact="diagnosis" post="(as of 20Â March 2020; summarized in Table 1)"/>
  <result pre="MERS-CoV A collection of six separate, industrial, MERS CoV RNA" exact="detection" post="kits focused on the PCR-RRT: (i) PowerChek (Kogene Biotech,"/>
  <result pre="the virus, although the serum in the early days of" exact="infection" post="was negative. This has indicated that patients had elevated"/>
  <result pre="days of illness [43]. Besides commonly used RT-PCR for the" exact="diagnosis" post="of MERS-CoV, several diagnostic procedures have been reported in"/>
  <result pre="[37,44]. The N-gene is recommended to be used as the" exact="screening" post="tool in RT-PCR analysis, whereas the Orf1b tool serves"/>
  <result pre="[44]. The US CDC distributed the real-time RT-PCR for the" exact="detection" post="of SARS-CoV-2 with reaction primers and specifically engineered probes"/>
  <result pre="The same primer and protocol could be used for the" exact="detection" post="of SARS-CoV-2 in particular based on high genomic similarities"/>
  <result pre="and understood by the participating analysts. Inappropriate processing, distribution or" exact="treatment" post="may result in false-negative results due to insufficient viral"/>
  <result pre="lead to a discrepancy between the PCR primers and the" exact="detection" post="probe sequence that may decrease the test efficiency or"/>
  <result pre="the next few months for research and development [15]. Serological" exact="testing" post="CDC is said to have a two-serological study procedure,"/>
  <result pre="to have a two-serological study procedure, by way of two" exact="screening" post="tests and a confirmation check to identify MERS-COV antibody"/>
  <result pre="identify MERS-COV antibody [15]. Enzyme-linked immunosorbent assay (ELISA) is a" exact="screening" post="procedure used to determine the existence and amount of"/>
  <result pre="in a second week or with delayed antibody development. Serological" exact="diagnosis" post="is more likely to be employed if nucleic amplification"/>
  <result pre="of cell entry, which could help the production of new" exact="infection" post="screening, vaccinations and treatment. Another report of the COVID-19"/>
  <result pre="test and is actually in use in China's therapeutic and" exact="testing" post="centers [50]. Out of 570 original research reviewed for"/>
  <result pre="tests. No population style studies were carried out at the" exact="screening" post="point on the SARS-CoV-2 (cell, species, human). The clinical"/>
  <result pre="potential vaccines [56â€&quot;63]. Essential proteins &amp;amp; their roles in viral" exact="infection" post="SARS-CoV-2, based on full-length phylogenetic genome review, is found"/>
  <result pre="1 [13]. Preventive approaches rely on hospital separation and diligent" exact="infection" post="management, including effective preventive intervention and emergency treatment for"/>
  <result pre="and diligent infection management, including effective preventive intervention and emergency" exact="treatment" post="for an affected hospital. For starters, during the processing"/>
  <result pre="moment in the standard clinical practices of China for SARS-CoV-2" exact="infection" post="[27]. However, the validity of using these compounds should"/>
  <result pre="patients are still managed adjunctively. Standard care is composed of" exact="isolation" post="and prevention measurements, supportive care for symptoms and complications"/>
  <result pre="to risks of deterioration in health, sudden respiratory failure and" exact="isolation" post="failure, inpatients setting are preferred when possible. Outpatients settings"/>
  <result pre="or in repurposed, nontraditional settings; or at home [69]. The" exact="isolation" post="and prevention measurements include isolating patients and all suspected"/>
  <result pre="patients and all suspected cases in a separate area. The" exact="isolation" post="should be continued for at least 2Â weeks after"/>
  <result pre="on routine bases. These agents might mask fever and delay" exact="diagnosis" post="and treatment [71]. Both paracetamol and NSAIDs can be"/>
  <result pre="bases. These agents might mask fever and delay diagnosis and" exact="treatment" post="[71]. Both paracetamol and NSAIDs can be considered to"/>
  <result pre="improving patients' survival and reducing the viral load of SARS-CoV-2" exact="infection" post="[77]. The investigations include antiviral drugs such as lopinavir,"/>
  <result pre="Yin-Tan Hospital, Wuhan, on 199 seriously ill patients of SARS-CoV-2" exact="infection" post="[80]. Male and nonpregnant patients of 18Â years or"/>
  <result pre="group received the standard care in hospital, and the other" exact="treatment" post="group received a combination of LPV/RTV (400 and 100Â"/>
  <result pre="daily plus the standard hospital care for 14Â days. The" exact="treatment" post="group showed no improvement in survival compared with control"/>
  <result pre="respectively [81]. No differences in the percentages of viral RNA" exact="detection" post="was found at different times points in the members"/>
  <result pre="outcomes include viral clearance (two constitutive negative results on qPCR" exact="detection" post="throughout 24Â h), changes in chest imaging (improvement in"/>
  <result pre="only higher in FPV group on day 14 of the" exact="treatment" post="compared with LPV/RTV group 91.4 and 62.2%. The FPV"/>
  <result pre="with LPV/RTV group, and no patients needed to discontinue the" exact="treatment" post="[73]. Therefore, FPV stands as a promising agent in"/>
  <result pre="further the role of FPV in the management of SARS-CoV-2" exact="infection" post="(NCT04303299, NCT04310228 and NCT04273763). FPV is being investigated as"/>
  <result pre="also showed promising in vitro activities by blocking the viral" exact="infection" post="of SARS-CoV-2, as demonstrated by Wang M. et al.,"/>
  <result pre="clinical case study for the first patient diagnosed with SARS-CoV-2" exact="infection" post="in USA has shown promising effectiveness of RDV [74]."/>
  <result pre="have differences in patients disease conditions (mild, moderate and severe)," exact="treatment" post="durations (5, 9 andÂ 10Â days), as well as"/>
  <result pre="recruiting patients to determine the efficacy of RBV for SARS-CoV-2" exact="infection" post="at the University of Hong Kong, Queen Mary Hospital."/>
  <result pre="has shown that the addition of arbidol to or LPV/RTV" exact="treatment" post="significantly provided additional benefits on viral clearance and patients'"/>
  <result pre="currently being investigated extensively for its promising activity against SARS-CoV-2" exact="infection" post="[96,97]. CQ is an old antimalarial drug with limited"/>
  <result pre="in vitro level, HCQ showed significant inhibition of the SAR-CoV-2" exact="infection" post="[46]. CQ and HCQ resulted in significant antiviral cytotoxicity"/>
  <result pre="WangÂ et al. have demonstrated potent blocking of SARS-COV-2 viral" exact="infection" post="by CQ (EC50Â =Â 1.13Â Î¼M; CC50Â &amp;gt;100Â Î¼M,"/>
  <result pre="Registry to test the CQ or HCQ efficiency on SARS-CoV-2" exact="infection" post="[97]. The clinical outcomes include time to clinical recovery,"/>
  <result pre="world, investigating CQ and HCQ effectiveness in the prevention and" exact="treatment" post="of SAR-CoV-2. Clinical trials were registered to the Clinicaltrials.gov"/>
  <result pre="clinical trials. FBV tablets combined with CQ phosphate in the" exact="treatment" post="of coronavirus pneumonia is being investigated in the ChiCTR2000030987"/>
  <result pre="are being studied [105]. The dosing system and duration of" exact="treatment" post="are still varied between different studies. For example, in"/>
  <result pre="the innate immune system of the patient to fight the" exact="infection" post="(immune senescence). SARS-CoV-2 blocks the interferon pathway and prevents"/>
  <result pre="It has potent anti-inflammatory effects and already approved for the" exact="treatment" post="of RA [110]. Tocilizumab is a biological disease-modifying antirheumatic"/>
  <result pre="to investigate the efficacy and tolerability of tocilizumab in the" exact="treatment" post="of patients with SARS-CoV-2 infection. Tocilizumab is to be"/>
  <result pre="trial for the efficacy and safety of tocilizumab in the" exact="treatment" post="of new coronavirus pneumonia, SARS-CoV-2. The study is being"/>
  <result pre="combined with tocilizumab versus FPV alone versus tocilizumab alone for" exact="treatment" post="of SARS-CoV-2 infection [117]. Sarilumab is another IL-6 blocker"/>
  <result pre="versus FPV alone versus tocilizumab alone for treatment of SARS-CoV-2" exact="infection" post="[117]. Sarilumab is another IL-6 blocker that is used"/>
  <result pre="died [27]. A study included 80 patients with confirmed SARS-CoV-2" exact="infection" post="received treatment of a single antibiotic (moxifloxacin) and RBV"/>
  <result pre="A study included 80 patients with confirmed SARS-CoV-2 infection received" exact="treatment" post="of a single antibiotic (moxifloxacin) and RBV antiviral therapy."/>
  <result pre="Another study was conducted on 46 patients with confirmed SARS-CoV-2" exact="infection" post="who received standard care of oxygen, cough relief, antiviral"/>
  <result pre="time of this review, the role of corticosteroids as adjunctive" exact="treatment" post="in the management of SARS-CoV-2 is still controversial. According"/>
  <result pre="(to compare the efficacy of different hormone doses in the" exact="treatment" post="of SARS-CoV-2 severe pneumonia in Wuhan, Hubei, China), and"/>
  <result pre="approach. Low-level radiation, statins and aspirin are suggested for the" exact="treatment" post="of SARS-CoV-2 pneumonia. This proposal stems from previous reports"/>
  <result pre="with SARS-CoV-2 Vero-hSLAM cells) after 48Â h of single ivermectin" exact="treatment" post="(5Â Î¼M) [126]. An observational study showed the survival"/>
  <result pre="yet) The discovery and development of new molecules against SARS-CoV-2" exact="infection" post="need time [129]. Besides, in silico discovery of molecules"/>
  <result pre="therapies as an option to reduce the symptoms of SARS-CoV-2" exact="infection" post="with baricitinib, and melatonin being the most related [131]."/>
  <result pre="a drug approved for RA, was identified by in silico" exact="screening" post="for anti-inflammatory drugs that could be potential therapies for"/>
  <result pre="for anti-inflammatory drugs that could be potential therapies for SARS-CoV-2" exact="infection" post="[132]. SAR-COV-2 enters lung cells by ACE2-mediated invasion. AP2-associated"/>
  <result pre="has been previously encouraged to be used for Ebola viral" exact="infection" post="[134]. As suggested by ChengÂ et al., melatonin could"/>
  <result pre="et al., melatonin could reduce the clinical symptoms of SARS-CoV-2" exact="infection" post="and prolong the survival time for the patient. Angiotensin"/>
  <result pre="it is still unclear how ACE2 is modified in SARS-CoV-2" exact="infection" post="[32,135]. Kruse has suggested that therapies that block the"/>
  <result pre="domain could be studied for their potential effectiveness against SARS-CoV-2" exact="infection" post="[136]. For example, using the small receptor-binding domain (RBD)"/>
  <result pre="for the function of proteases 3CLpro and Plpro in SARS-CoV" exact="infection" post="[141]. These candidates are also undergoing studies in research"/>
  <result pre="[141,142]. Î±-ketoamide inhibitors were previously synthesized and tested against MERS-CoV" exact="infection" post="by Liu research group. Î±-ketoamide derivatives have shown picomolar"/>
  <result pre="inhibitor and considered Î±-ketoamide inhibitors as promising agents for SARS-CoV-2" exact="infection" post="[140]. Traditional Chinese medicines therapy Traditional Chinese medicines (TCMs)"/>
  <result pre="[143,145,146]. Moreover, TCMs were included in the guideline for the" exact="diagnosis" post="and treatment of COVID-19 by the National Health Commission"/>
  <result pre="TCMs were included in the guideline for the diagnosis and" exact="treatment" post="of COVID-19 by the National Health Commission of the"/>
  <result pre="a study based on historical records on the prevention and" exact="treatment" post="of infections using TCM, TCM prevention programs issued by"/>
  <result pre="have concluded that TCMs could contain direct constituents for the" exact="treatment" post="of COVID-19 [139]. In this study, it has been"/>
  <result pre="process. Several pharmaceutical companies enter the race to find a" exact="treatment" post="for SARS-CoV-2 infection, relieve its symptoms or to reduce"/>
  <result pre="antimalarials and immunotherapeutics aimed at diverse molecular associations linked to" exact="infection" post="and replication. This review focuses primarily on agents reported"/>
  <result pre="other pneumonia-causing viruses or infections. This primarily consists of preventive" exact="treatment" post="and supplementation with oxygen if required. The active research"/>
  <result pre="RajnikM , CuomoA , DulebohnSC , DiNapoli RFeatures, evaluation and" exact="treatment" post="coronavirus (COVID-19). StatPearls, Treasure Island (FL) (2020). 4.ChenWH ,"/>
  <result pre=", KendallMet al.Quantifying SARS-CoV-2 transmission suggests epidemic control with digital" exact="contact tracing." post="Science (2020). â€¢ Modeling work indicates that the digitization"/>
  <result pre="Modeling work indicates that the digitization of cell phone touch" exact="tracing" post="will contribute to a permanent disease elimination. 6.WrappD ,"/>
  <result pre="Infect. Dis. (2020). 15.collab: RVB. Division of viral diseases. Real-time" exact="rt-pcr" post="panel for detection 2019- novel coronavirus. (2020).www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detectioninstructions.pdf?sfvrsn=3aa07934_2 16.AndersenKG ,"/>
  <result pre="15.collab: RVB. Division of viral diseases. Real-time rt-pcr panel for" exact="detection" post="2019- novel coronavirus. (2020).www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detectioninstructions.pdf?sfvrsn=3aa07934_2 16.AndersenKG , RambautA , LipkinWI"/>
  <result pre="216â€&quot;219 (2016).27106390 31.collab: WHO. Novel coronavirus (2019-ncov) technical guidance: laboratory" exact="testing" post="for 2019-ncov in humans. (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance 32.LiuC , ZhouQ"/>
  <result pre="validation of six commercial Middle East Respiratory Syndrome coronavirus RNA" exact="detection" post="kits based on real-time reverse-transcription PCR. Ann. Lab. Med.36(5),"/>
  <result pre="J.18(11), e23874 (2016).28191331 37.LauSK , CheX-Y , WooPCet al.SARS coronavirus" exact="detection" post="methods. Emerg. Infect. Dis.11(7), 1108 (2005).16022791 38.LauLT , FungY-WW"/>
  <result pre="1290â€&quot;1296 (2003).14652014 39.JiangSS , ChenT-C , YangJ-Yet al.Sensitive and quantitative" exact="detection" post="of severe acute respiratory syndrome coronavirus infection by real-time"/>
  <result pre="al.Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus" exact="infection" post="by real-time nested polymerase chain reaction. Clin. Infect. Dis.38(2),"/>
  <result pre="of severe acute respiratory syndrome coronavirus infection by real-time nested" exact="polymerase chain reaction." post="Clin. Infect. Dis.38(2), 293â€&quot;296 (2004).14699465 40.HeQ , ChongKH ,"/>
  <result pre="ChongKH , ChngHHet al.Development of a Western blot assay for" exact="detection" post="of antibodies against coronavirus causing severe acute respiratory syndrome."/>
  <result pre="of 2019 novel coronavirus (2019-ncov) in suspected human cases by" exact="rt-pcr" post="lks faculty of medicine school of public health2020). www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4"/>
  <result pre="CD26. Emerg. Microbes Infect.9(1), 601â€&quot;604 (2020).32178593 50.Bgi develops real-time fluorescent" exact="rt-pcr" post="kit for detecting the 2019 novel coronavirus2020). www.bgi.com/global/company/news/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus/ 51.LinJ"/>
  <result pre="healthy volunteers. (2020). https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;amp;cond=Mers+CoV&amp;amp;draw=2&amp;amp;rank=7 55.Efficacy and safety of hydroxychloroquine for" exact="treatment" post="of pneumonia caused by 2019-ncov (hc-ncov)2020). https://clinicaltrials.gov/ct2/show/NCT04261517 56.AhmedSF ,"/>
  <result pre="62.ShoenfeldYCorona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis," exact="treatment" post="and vaccine planning. Autoimmun. Rev. (2020) (Epub ahead of"/>
  <result pre="entry inhibitors by drug repurposing using in silico structure-based virtual" exact="screening" post="approach (2020). 67.FaragA , WangP , AhmedM , SadekHIdentification"/>
  <result pre="69.collab: World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. March 2020 (2020)."/>
  <result pre="IngegnoliF , DeLucia O , CincinelliG , CimazR , CaporaliRCOVID-19" exact="infection" post="and rheumatoid arthritis: faraway, so close!Autoimmun. Rev.19(5), 102523 (2020)."/>
  <result pre="shape and pharmacophore distribution. (2020). 10.26434/chemrxiv.12084690.v2 96.KearneyJChloroquine as a potential" exact="treatment" post="and prevention measure for the 2019 novel coronavirus: a"/>
  <result pre="TianZ , YangXBreakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. Bio. Sci."/>
  <result pre=", PhilippeParolaa , VanThuan Hoanget al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell. Dis.6(1), 1â€&quot;4 (2020). 101.YaoX , YeF"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin."/>
  <result pre="EmeryP , Van VollenhovenRet al.Tocilizumab monotherapy versus adalimumab monotherapy for" exact="treatment" post="of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase"/>
  <result pre="immunosuppression. Lancet395(10229), P1033â€&quot;1034 (2020). 114.XuX , HanM , LiTet al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. Proc. Natl Acad."/>
  <result pre="TianZ , YangXBreakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. Biosci Trends14(1),"/>
  <result pre="JiangW , HeQet al.Early, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
  <result pre="14 (2020).32194980 132.RichardsonP , GriffinI , TuckerCet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet395(10223), e30â€&quot;e31 (2020).32032529 133.TanD-X"/>
  <result pre="139.ZhangD-H , WuK-L , ZhangX , DengS-Q , PengBIn silico" exact="screening" post="of Chinese herbal medicines with the potential to directly"/>
  <result pre=", WangJ , LiY , ChenXTraditional Chinese medicine in the" exact="treatment" post="of patients infected with 2019-new coronavirus (SARS-CoV-2): a review"/>
  <result pre=", CaiL , ChengZ-Set al.A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre=", ChengZ-Set al.A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)."/>
 </snippets>
</snippetsTree>
